| Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups JF Yale, U Bodholdt, AM Catarig, S Catrina, A Clark, NR Ekberg, U Erhan, ... BMJ Open Diabetes Research and Care 10 (2), e002619, 2022 | 25 | 2022 |
| Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes VR Aroda, U Erhan, P Jelnes, JJ Meier, MT Abildlund, R Pratley, T Vilsbøll, ... Diabetes, Obesity and Metabolism 25 (5), 1385-1397, 2023 | 13 | 2023 |
| FC 124: real-world use of once-weekly semaglutide by baseline estimated glomerular filtration rate—a post-hoc analysis of pooled data from the sure studies (Canada, Denmark … G Rudofsky, AM Catarig, U Erhan, R Jain, S Tang Knudsen, P Saravanan, ... Nephrology Dialysis Transplantation 37 (Supplement_3), gfac126. 003, 2022 | 1 | 2022 |
| Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK study P Holmes, AM Catarig, A Clark, U Erhan, T Sathyapalan DIABETIC MEDICINE 38, 2021 | 1 | 2021 |
| Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies JF Yale, AM Catarig, SB Catrina, U Erhan, T Sathyapalan, B Schultes, ... Diabetologie und Stoffwechsel 17 (S 01), P 076, 2022 | | 2022 |
| REAL-WORLD USE OF ONCE-WEEKLY SEMAGLUTIDE BY BASELINE ESTIMATED GLOMERULAR FILTRATION RATE-A POST-HOC ANALYSIS OF POOLED DATA FROM THE SURE STUDIES (CANADA, DENMARK/SWEDEN … G Rudofsky, AM Catarig, U Erhan, R Jain, ST Knudsen, P Saravanan, ... NEPHROLOGY DIALYSIS TRANSPLANTATION 37, I894-I895, 2022 | | 2022 |
| Patients reaching treatment targets with once-weekly semaglutide in real‑world practice: pooled analysis of four SURE studies R Rasalam, G Rudofsky, U Bodholdt, AM Catarig, N Ekberg, U Erhan, ... Novo Nordisk, 2022 | | 2022 |
| Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies JF Yale, AM Catarig, SB Catrina, U Erhan, T Sathyapalan, B Schultes, ... Canadian Journal of Diabetes 45 (7), S28, 2021 | | 2021 |
| Patients reaching treatment targets with once-weekly semaglutide in real-world practice: pooled analysis of four SURE studies G Rudofsky, U Bodholdt, AM Catarig, NR Ekberg, U Erhan, JF Liutkus, ... DIABETOLOGIA 64 (SUPPL 1), 230-231, 2021 | | 2021 |
| Mobile health application as a real-world data resource: self-recorded weight reduction with once-weekly semaglutide U Bodholdt, S Birot, AM Catarig, U Erhan, FK Knop | | 2021 |
| USE OF A MOBILE HEALTH APPLICATION TO SUPPORT INITIATION OF ONCE-WEEKLY SEMAGLUTIDE: AN ANALYSIS FROM 13 COUNTRIES OF USER ENGAGEMENT DURING THE DOSE ESCALATION PERIOD U Erhan, S Birot, U Bodholdt, F Knop DIABETES TECHNOLOGY & THERAPEUTICS 23, A46-A46, 2021 | | 2021 |
| 64-Real-World Use of Once-Weekly Semaglutide in Patients With Type 2 Diabetes: Results From SURE Canada JF Yale, AM Catarig, U Erhan, K Grau, A Klimek-Abercrombie, L Reardon, ... Canadian Journal of Diabetes 44 (7), S27-S28, 2020 | | 2020 |
